Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
ConditionHepatocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNiguarda Hospital
About this trial
This is a national, observational, retrospective, cross-sectional, non-profit study focused on patients with HCC. The study aims to characterize the expression and function of novel noncoding regulatory transcripts, including those containing TEsin the microenvironment of liver tumors, with emphasis on their role in T cell dysfunction.
Eligibility criteria
Qualifiers
Histological/radiological (LR-4 o 5)diagnosis of hepatocellular carcinoma (HCC).
Solid tumor fresh tissue availability from HCC biospy or surgical resectionas per standard clinical practice, and/orHCC FFPE archival samples availability.
Capability of understanding and signing an inform consent form.
Known hepatits B and C status, including HBeAg (positive or negative), viral load (HBVDNA e HCV-RNA), HCV genotype, whether sustained virological response (SVR)was obtainedand potential antiviral treatments received (including direct antiretroviral therapy(DAA)and interferon). These parameters will be exploited to stratify patients and analyze the impact of the virological status on microenvironmental immunological features, with particular regards to immunesuppression mechanisms.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Collection of tumor tissue (Fresh or/and archival FFPE), blood samples
Treatment groups
270 Participants
are divided into 1 treatment groupSponsors and collaborators
Niguarda Hospital
Lead sponsor
San Raffaele University Hospital, Italy
Collaborator
Fondazione Istituto Nazionale Genetica Molecolare - INGM
Collaborator
University of Milan
Collaborator
Source ClinicalTrials.gov